Results 1 to 10 of about 461 (125)

Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors [PDF]

Nature Communications
Obesity is a major and increasingly prevalent chronic metabolic disease with numerous comorbidities. While recent incretin-based therapies have provided pharmaceutical inroads into treatment of obesity, there remains an ongoing need for additional ...
Patrick Sexton, Jianjun Cao, Matthew Belousoff   +2 more
exaly   +8 more sources

Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3Research in context [PDF]

EBioMedicine
Summary: Background: Amylin (AmyR) and calcitonin (CTR) receptor co-agonists are currently in Phase II/III clinical trials for obesity treatment. Amylin binds to a heterodimeric receptor composed of CTR and the receptor activity modifying proteins 1, 2 ...
Alexandra Oliveira Carvas, Andrea Leuthardt, Patricia Kulka, Greta Lommi, Shad Hassan, Bernd Coester, Sofia Lundh, Tune Pers, Anna Secher, Kirsten Raun, Thomas A. Lutz, Christelle Le Foll   +11 more
doaj   +8 more sources

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials [PDF]

Endocrinology, Diabetes & Metabolism
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality.
Sultan Hamarsheh, Abdel Rahman Jaber, Omar Abu‐Khazneh, Celina R. Andonie, Saleem Majadleh, Anwar Zahran, Hazem Ayesh   +6 more
doaj   +4 more sources

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis [PDF]

Indian Journal of Endocrinology and Metabolism
No meta-analysis has analysed role of cagrilintide as weight-loss medication in obese individuals. Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination ...
Ameya Joshi, Deep Dutta, Lakshmi Nagendra   +2 more
exaly   +6 more sources

Novel Amylin‐Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta‐Analysis [PDF]

Endocrinology, Diabetes & Metabolism
Background Long‐acting amylin‐based therapies (ABTs) are emerging anti‐obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and
A. B. M. Kamrul‐Hasan, Ibrahim Khalil, Kunal Mahajan, Deep Dutta, Mainak Banerjee, Joseph M. Pappachan   +5 more
doaj   +3 more sources

Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro [PDF]

Journal of Cachexia, Sarcopenia and Muscle
Background Incretin‐based therapies such as glucagon‐like peptide‐1 receptor agonists (GLP‐1Ras), dual GLP‐1/GIP agonists and amylin analogues have demonstrated significant weight loss benefits.
Victoria Old, Melanie Davies, Matthew Denniff, Pratik Choudhary, Nicholas Eastley, Robert U. Ashford, Emma Watson   +6 more
doaj   +3 more sources

Cagrilintide plus semaglutide for obesity management

Lancet, The, 2021
Cagrilintide is a novel long-acting amylin receptor agonist, which has shown a potent induction of weight loss. Interestingly, cagrilintide is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) derived from an amylin backbone. Another class of long-acting DACRAs exists, namely the KBPs.
Becerril S, Gema Fruhbeck
exaly   +11 more sources

Development of Cagrilintide, a Long-Acting Amylin Analogue [PDF]

Journal of Medicinal Chemistry, 2021
A hallmark of the pancreatic hormone amylin is its high propensity toward the formation of amyloid fibrils, which makes it a challenging drug design effort. The amylin analogue pramlintide is commercially available for diabetes treatment as an adjunct to insulin therapy but requires three daily injections due to its short half-life.
Eva Johansson, Ulrich Sensfuss, Simone Fulle   +2 more
exaly   +3 more sources

Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity [PDF]

Journal of Obesity & Metabolic Syndrome
Amylin is a pancreatic peptide hormone that regulates blood glucose levels and appetite. This review outlines the physiological role of amylin and highlights recent clinical studies exploring its therapeutic potential in diabetes and obesity.
Chae Won Chung, Jaetaek Kim
doaj   +2 more sources

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept [PDF]

Molecular Metabolism
Objectives: Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity.
Daniel A. Briere, Hongchang Qu, Katherine Lansu, Minxia Michelle He, Julie S. Moyers, Tamer Coskun, Annie Long, Dawn Allen, Libbey O'Farrell, Breanna Bowen, Edward Pratt, Beth Tidemann-Miller, Lai San Tham, Hilda Ibriga, Jorge Alsina-Fernandez, Kieren J. Mather, Axel Haupt, Shobha N. Bhattachar   +17 more
doaj   +2 more sources